Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Anika Therapeutics, Inc. operates as an integrated orthopedic medicines company. The Company develops, manufactures, and commercializes therapeutic pain management solutions based on its proprietary hyaluronic acid (HA) technology. Anika Therapeutics markets its products worldwide.
Website: anikatherapeutics.com



Growth: Bad revenue growth rate -28.2%, there is slowdown compared to average historical growth rates -7.8%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -61.9%. On average the margin is improving steadily. Gross margin is high, +56.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.07 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 1.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 14.9% higher than minimum and 71.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -2.2x by EV / Sales multiple

Key Financials (Download financials)

Ticker: ANIK
Share price, USD:  (-0.9%)9.31
year average price 11.62  


year start price 16.31 2025-01-25

max close price 17.97 2025-02-05

min close price 8.10 2025-07-30

current price 9.31 2026-01-24
Common stocks: 14 419 000

Dividend Yield:  0.0%
EV / Sales: 0.9x
Margin (EBITDA LTM / Revenue): -61.9%
Fundamental value created in LTM:
Market Cap ($m): 134
Net Debt ($m): -35
EV (Enterprise Value): 99
Price to Book: 0.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-23businesswire.com

ANIK INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Anika Therapeutics, Inc.

2025-12-30businesswire.com

ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP

2025-11-05globenewswire.com

Anika Reports Third Quarter 2025 Financial Results

2025-10-09globenewswire.com

ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders

2025-09-25globenewswire.com

ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm

2025-09-10globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK

2025-08-29globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK

2025-08-26globenewswire.com

ANIKA ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm

2025-08-21globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK

2025-08-17globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437
fillingDate 2025-11-05 2025-07-30 2024-11-04 2024-08-08 2024-05-08 2023-11-03 2023-08-08 2023-05-09 2022-11-09
acceptedDate 2025-11-05 16:01:00 2025-07-30 16:12:28 2025-03-14 18:33:14 2024-11-04 16:41:12 2024-08-08 17:21:03 2024-05-08 17:15:37 2024-03-15 12:20:07 2023-11-02 17:41:52 2023-08-08 17:15:17 2023-05-09 17:15:26 2023-03-16 15:37:56 2022-11-09 14:31:46 2022-03-10 19:43:36 2021-03-05 17:18:17
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 28M 28M 120M 39M 42M 41M 121M 41M 44M 38M 114M 40M 148M 130M
costOfRevenue 12M 14M 44M 37M 15M 16M 38M 17M 15M 15M 41M 17M 65M 61M
grossProfit 16M 14M 76M 1M 27M 25M 83M 25M 29M 23M 73M 23M 83M 69M
grossProfitRatio 0.56 0.509 0.037 0.653 0.608 0.602 0.654 0.602 0.566
researchAndDevelopmentExpenses 7M 6M 26M 7M 7M 8M 22M 8M 9M 8M 18M 7M 27M 23M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 12M 12M 56M 19M 20M 22M 60M 25M 24M 27M 51M 21M 74M 60M
otherExpenses 0 0 0 3M 0 0 0 0 0 0 0 0 -21M 14M
operatingExpenses 19M 19M 81M 29M 27M 30M 82M 33M 33M 35M 70M 29M 80M 97M
costAndExpenses 31M 32M 125M 67M 42M 46M 120M 49M 48M 50M 110M 46M 145M 159M
interestIncome 0 214 000 406 000 0 0 2M 635 000 561 000 0 654 000 0 498 000
interestExpense 0 0 0 0 592 000 0 0 561 000 539 000 0 436 000 800 000
depreciationAndAmortization 1M 1M 8M 2M 2M 3M 14M 4M 4M 4M 14M 0 14M 13M
ebitda -833 000 -3M 3M -25M 2M -2M 15M -8M -81 000 -9M 18M -6M -4M -1M
ebitdaratio -0.03 -0.098 -0.656 0.053 -0.061 -0.185 -0.002 -0.237 -0.144
operatingIncome -3M -4M -5M -28M 161 000 -5M 844 000 -8M -4M -13M 4M -6M 3M -28M
operatingIncomeRatio -0.116 -0.148 -0.723 0.004 -0.125 -0.185 -0.082 -0.331 -0.144
totalOtherIncomeExpensesNet 997 000 214 000 2M 406 000 595 000 592 000 2M 635 000 561 000 539 000 654 000 436 000 -188 000 -302 000
incomeBeforeTax -2M -4M -3M -28M 756 000 -4M 3M -7M -3M -12M 4M -5M 2M -29M
incomeBeforeTaxRatio -0.08 -0.141 -0.712 0.018 -0.11 -0.17 -0.069 -0.317 -0.133
incomeTaxExpense 939 000 681 000 6M 2M 844 000 43 000 7M -463 000 -329 000 -2M 2M -1M -2M -5M
netIncome -2M -4M -56M -30M -88 000 -5M -83M -7M -3M -10M -15M -4M 4M -24M
netIncomeRatio -0.084 -0.141 -0.772 -0.002 -0.111 -0.159 -0.062 -0.273 -0.104
eps -0.16 -0.28 -3.83 -2.03 -0.006 -0.31 -5.64 -0.45 -0.19 -0.71 -1.02 -0.29 0.29 -1.69
epsdiluted -0.16 -0.28 -2.03 -0.006 -0.31 -0.45 -0.19 -0.71 -0.29
weightedAverageShsOut 14M 14M 15M 15M 15M 15M 15M 15M 15M 15M 15M 15M 14M 14M
weightedAverageShsOutDil 14M 14M 15M 15M 15M 15M 15M 15M 15M 15M 15M 15M 15M 14M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-17 2024-03-15 2023-03-16 2022-03-11 2021-03-05
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 0 2M 654 000 0 -302 000
ebit -5M 844 000 4M -18M -14M
nonOperatingIncomeExcludingInterest 0 0 0 21M -14M
netIncomeFromContinuingOperations -9M -3M 2M 4M -24M
netIncomeFromDiscontinuedOperations -48M -79M -17M 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -56M -83M -15M 4M -24M
epsDiluted -3.83 -5.64 -1.02 0.28 -1.69

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437
fillingDate 2025-11-05 2025-07-30 2024-11-04 2024-08-08 2024-05-08 2023-11-03 2023-08-08 2023-05-09 2022-11-09
acceptedDate 2025-11-05 16:01:00 2025-07-30 16:12:28 2025-03-14 18:33:14 2024-11-04 16:41:12 2024-08-08 17:21:03 2024-05-08 17:15:37 2024-03-15 12:20:07 2023-11-02 17:41:52 2023-08-08 17:15:17 2023-05-09 17:15:26 2023-03-16 15:37:56 2022-11-09 14:31:46 2022-03-10 19:43:36 2021-03-05 17:18:17
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 58M 53M 56M 62M 63M 69M 69M 71M 65M 80M 86M 88M 94M 96M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 3M
cashAndShortTermInvestments 58M 53M 56M 62M 63M 69M 69M 71M 65M 80M 86M 88M 94M 98M
netReceivables 22M 24M 24M 28M 34M 32M 26M 35M 37M 31M 35M 34M 30M 24M
inventory 16M 17M 24M 40M 51M 49M 24M 44M 43M 41M 40M 37M 36M 46M
otherCurrentAssets 5M 5M 11M 6M 7M 9M 44M 8M 8M 9M 0 9M 0 0
totalCurrentAssets 102M 99M 114M 136M 155M 159M 163M 157M 152M 160M 170M 168M 169M 177M
propertyPlantEquipmentNet 65M 66M 65M 72M 75M 74M 65M 75M 78M 79M 79M 78M 69M 73M
goodwill 8M 8M 7M 8M 7M 7M 8M 7M 7M 7M 7M 7M 8M 8M
intangibleAssets 2M 2M 2M 3M 4M 4M 3M 69M 71M 73M 75M 77M 82M 91M
goodwillAndIntangibleAssets 10M 10M 10M 11M 11M 12M 10M 76M 78M 80M 82M 83M 90M 100M
longTermInvestments 6M 0 0 0 -1 0 0 0 0 0 0 0 0 0
taxAssets 1M 1M 1M 1M 1M 1M 1M 1M 1M 2M 1M 0 0 0
otherNonCurrentAssets 6M 12M 14M 11M 20M 18M 31M 19M 19M 18M 17M 18M 20M 15M
totalNonCurrentAssets 88M 88M 89M 95M 108M 105M 107M 171M 177M 179M 180M 180M 179M 188M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 189M 188M 203M 231M 263M 264M 271M 328M 329M 339M 349M 348M 348M 366M
accountPayables 5M 5M 6M 7M 10M 10M 6M 8M 8M 9M 9M 8M 8M 9M
shortTermDebt 2M 2M 0 2M 2M 2M 0 2M 2M 2M 0 2M 0 0
taxPayables 0 0 63 000 82 000 77 000 1M 1M 819 000 931 000 889 000 810 000 0 0 0
deferredRevenue 0 0 0 0 77 000 1M 0 -2M -2M 0 0 0 0 0
otherCurrentLiabilities 13M 9M 12M 16M 14M 15M 19M 20M 16M 18M 11M 16M 14M 20M
totalCurrentLiabilities 19M 16M 23M 25M 26M 28M 31M 28M 23M 29M 28M 26M 30M 37M
longTermDebt 23M 23M 0 25M 26M 26M 0 27M 28M 28M 0 29M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 2M 3M 4M 6M 7M 10M 12M
otherNonCurrentLiabilities 761 000 756 000 1M 806 000 407 000 403 999 1M 400 000 401 000 399 000 398 000 26M 1M 24M
totalNonCurrentLiabilities 24M 24M 25M 26M 26M 27M 27M 30M 31M 33M 36M 36M 31M 56M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 23M 25M 26M 28M 28M 26M 28M 27M 30M 30M 31M 29M 21M 22M
totalLiabilities 43M 40M 49M 52M 52M 55M 58M 58M 55M 61M 64M 63M 60M 93M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 144 000 144 000 144 000 147 000 148 000 148 000 147 000 146 000 147 000 147 000 146 000 146 000 144 000 143 000
retainedEarnings 60M 63M 72M 94M 123M 124M 128M 191M 198M 200M 211M 216M 226M 221M
accumulatedOtherComprehensiveIncomeLoss -5M -5M -7M -6M -6M -6M -6M -7M -6M -6M -6M -7M -6M -5M
othertotalStockholdersEquity 91M 89M 92M 93M 91M 86M 82M 83M 77M
totalStockholdersEquity 147M 148M 154M 180M 210M 209M 212M 270M 274M 278M 286M 285M 287M 272M
totalEquity 147M 148M 154M 180M 210M 209M 212M 270M 274M 278M 286M 285M 287M 272M
totalLiabilitiesAndStockholdersEquity 189M 188M 231M 263M 264M 328M 329M 339M 348M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 189M 188M 203M 231M 263M 264M 271M 328M 329M 339M 349M 348M 348M 366M
totalInvestments 6M 0 0 0 -1 0 0 0 0 0 0 0 0 3M
totalDebt 25M 25M 26M 28M 28M 28M 28M 27M 30M 30M 31M 29M 21M 22M
netDebt -33M -28M -30M -35M -35M -40M -41M -43M -35M -49M -55M -59M -73M -73M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-17 2024-03-15 2023-03-16 2022-03-11 2021-03-05
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 24M 26M 35M 30M 24M
otherReceivables 0 0 0 0 0
prepaids 0 0 9M 8M 9M
totalPayables 6M 7M 10M 8M 9M
otherPayables 63 000 1M 810 000 0 0
accruedExpenses 4M 3M 5M 7M 6M
capitalLeaseObligationsCurrent 2M 2M 2M 2M 2M
capitalLeaseObligationsNonCurrent 24M 26M 29M 19M 21M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 89M 90M 81M 67M 55M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK ANIK
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437 898 437
fillingDate 2025-11-05 2025-07-30 2024-11-04 2024-08-08 2024-05-08 2023-11-03 2023-08-08 2023-05-09 2022-11-09
acceptedDate 2025-11-05 16:01:00 2025-07-30 16:12:28 2025-03-14 18:33:14 2024-11-04 16:41:12 2024-08-08 17:21:03 2024-05-08 17:15:37 2024-03-15 12:20:07 2023-11-02 17:41:52 2023-08-08 17:15:17 2023-05-09 17:15:26 2023-03-16 15:37:56 2022-11-09 14:31:46 2022-03-10 19:43:36 2021-03-05 17:18:17
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -2M -4M -56M -30M -88 000 -5M -83M -7M -3M -10M -15M -4M 4M -24M
depreciationAndAmortization 1M 1M 8M 2M 2M 3M 14M 4M 4M 4M 14M 3M 14M 15M
deferredIncomeTax 3000 -3000 260 000 -184 000 17 000 193 000 -6M -1M -904 000 -2M -5M -1M -2M -4M
stockBasedCompensation 2M 3M 13M 3M 4M 4M 15M 4M 4M 4M 14M 4M 11M 0
changeInWorkingCapital 4M -4M -13M 12M -8M -4M -12M 3M -14M 642 000 -12M -3M -15M -13M
accountsReceivables 1M -2M 3M 5M -2M 4M -1M 2M -6M 4M -6M -2M -6M 6M
inventory -443 000 2M -9M -3M -5M -4M -11M -2M -3M -3M -7M -2M -7M -14M
accountsPayables 231 000 -1M -3M -3M 148 000 401 000 -11 000 -290 000 -316 000 -713 000 2M 249 000 -1M 822 000
otherWorkingCapital 3M -2M -5M 13M -2M -4M 589 000 4M -4M 361 000 -1M 1M -783 000 -6M
otherNonCashItems 1M 4M 53M 18M 15M 11M 70M 4M 1M 1M 8M 4M -5M 39M
netCashProvidedByOperatingActivities 7M -189 000 5M 5M -1M -126 000 -2M 6M -8M -4M 4M 3M 8M 13M
investmentsInPropertyPlantAndEquipment -2M -1M -8M -1M -3M -2M -5M -741 000 -1M -1M -7M -2M -5M -2M
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 0 -476 000 -95M
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 -20M
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 3M 45M
otherInvestingActivites 155 000 928 000 -600 000 0 0 0 0 0 0
netCashUsedForInvestingActivites -2M -539 000 -2M -3M -2M -741 000 -1M -1M -2M
debtRepayment 0 0 0 0 0 0 0 0 -231 000
commonStockIssued 0 261 000 0 0 23 000 0 486 000 0 0
commonStockRepurchased 0 0 -11M -4M -1M -2M -5M -110 000 -5M 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -13 000 -82 000 -22 000 -205 000 -2M -110 000 -429 000 -2M -4M
netCashUsedProvidedByFinancingActivities -13 000 179 000 -4M -1M -2M -110 000 -5M -2M -5M
effectOfForexChangesOnCash -302 000 345 000 -48 000 337 000 -224 000 -31 000 79 000 -54 000 27 000 30 000 -130 000 -22 000 69 000 327 000
netChangeInCash 5M -204 000 -16M -454 000 -6M -4M -13M 6M -15M -7M -8M -4M -1M -62M
cashAtEndOfPeriod 58M 53M 57M 62M 63M 69M 73M 71M 65M 80M 86M 88M 94M 96M
cashAtBeginningOfPeriod 53M 53M 73M 63M 69M 73M 86M 65M 80M 86M 94M 91M 96M 157M
operatingCashFlow 7M -189 000 5M 5M -1M -126 000 -2M 6M -8M -4M 4M 3M 8M 13M
capitalExpenditure -2M -1M -8M -1M -3M -2M -5M -741 000 -1M -1M -7M -2M -5M -2M
freeCashFlow 5M -2M -2M 4M -4M -2M -7M 6M -10M -5M -3M 1M 3M 11M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-17 2024-03-15 2023-03-16 2022-03-11 2021-03-05
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -600 000 0 0 0 0
netCashProvidedByInvestingActivities -8M -5M -7M -3M -71M
netDebtIssuance 0 0 -284 000 -201 000 -558 000
longTermNetDebtIssuance 0 0 -284 000 -201 000 -350 000
shortTermNetDebtIssuance 0 0 0 0 -208 000
netStockIssuance -11M -5M 0 0 2M
netCommonStockIssuance -11M -5M 0 0 2M
commonStockIssuance 0 0 0 0 2M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -2M -1M -5M -7M -5M
netCashProvidedByFinancingActivities -13M -6M -5M -7M -4M
incomeTaxesPaid 4M 3M 106 000 1M 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-05 ET (fiscal 2025 q3)
2025 q2
2025-07-30 ET (fiscal 2025 q2)
2025 q1
2025-05-09 ET (fiscal 2025 q1)
2024 q4
2025-03-12 ET (fiscal 2024 q4)
2024 q3
2024-11-02 ET (fiscal 2024 q3)
2024 q2
2024-08-11 ET (fiscal 2024 q2)
2024 q1
2024-05-08 ET (fiscal 2024 q1)
2023 q4
2024-03-13 ET (fiscal 2023 q4)
2023 q3
2023-11-03 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-13 ET (fiscal 2023 q1)
2022 q4
2023-03-06 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-06 ET (fiscal 2022 q2)
2022 q1
2022-05-07 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-11-05 16:01 ET
Anika Therapeutics reported for 2025 q3
SEC form 8
2025-11-05 07:20 ET
Anika Therapeutics published news for 2025 q3
SEC form 8
2025-11-05 07:20 ET
Anika Therapeutics published news for 2025 q3
SEC form 8
2025-11-05 07:20 ET
Anika Therapeutics published news for 2025 q3
SEC form 10
2025-07-30 20:12 ET
Anika Therapeutics reported for 2025 q2
SEC form 8
2025-07-30 11:21 ET
Anika Therapeutics published news for 2025 q2
SEC form 8
2025-07-30 11:21 ET
Anika Therapeutics published news for 2025 q2
SEC form 8
2025-07-30 11:15 ET
Anika Therapeutics published news for 2025 q2
SEC form 8
2025-07-30 11:15 ET
Anika Therapeutics published news for 2025 q2
SEC form 10
2025-05-09 18:30 ET
Anika Therapeutics reported for 2025 q1
SEC form 8
2025-05-09 11:20 ET
Anika Therapeutics published news for 2025 q1
SEC form 8
2025-05-09 11:20 ET
Anika Therapeutics published news for 2025 q1
SEC form 10
2025-05-09 00:00 ET
Anika Therapeutics published news for 2025 q1
SEC form 10
2025-03-17 00:00 ET
Anika Therapeutics published news for 2024 q4
SEC form 8
2025-03-12 20:10 ET
Anika Therapeutics reported for 2024 q4
SEC form 8
2025-03-12 20:10 ET
Anika Therapeutics published news for 2024 q4
SEC form 10
2024-11-04 16:41 ET
Anika Therapeutics reported for 2024 q3
SEC form 8
2024-10-31 07:20 ET
Anika Therapeutics published news for 2024 q3
SEC form 8
2024-10-31 07:20 ET
Anika Therapeutics published news for 2024 q3
SEC form 10
2024-08-08 17:21 ET
Anika Therapeutics published news for 2024 q2
SEC form 8
2024-08-08 16:10 ET
Anika Therapeutics reported for 2024 q2
SEC form 8
2024-08-08 16:10 ET
Anika Therapeutics published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Anika Therapeutics published news for 2024 q2
SEC form 10
2024-05-08 00:00 ET
Anika Therapeutics reported for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Anika Therapeutics published news for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Anika Therapeutics published news for 2024 q1
SEC form 10
2024-03-15 12:20 ET
Anika Therapeutics published news for 2023 q4
SEC form 10
2024-03-15 00:00 ET
Anika Therapeutics published news for 2023 q4
SEC form 8
2024-03-13 16:10 ET
Anika Therapeutics reported for 2023 q4
SEC form 8
2024-03-13 16:10 ET
Anika Therapeutics published news for 2023 q4
SEC form 10
2023-11-03 00:00 ET
Anika Therapeutics published news for 2023 q3
SEC form 10
2023-11-02 17:41 ET
Anika Therapeutics published news for 2023 q3
SEC form 8
2023-11-02 16:11 ET
Anika Therapeutics reported for 2023 q3
SEC form 10
2023-08-08 17:15 ET
Anika Therapeutics reported for 2023 q2
SEC form 6
2023-08-08 16:11 ET
Anika Therapeutics published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Anika Therapeutics published news for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Anika Therapeutics published news for 2023 q2
SEC form 6
2023-06-21 16:50 ET
Anika Therapeutics published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Anika Therapeutics published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Anika Therapeutics published news for 2023 q1
SEC form 10
2023-03-16 00:00 ET
Anika Therapeutics reported for 2022 q4
SEC form 8
2023-03-06 00:00 ET
Anika Therapeutics reported for 2022 q4
SEC form 10
2022-11-09 00:00 ET
Anika Therapeutics reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Anika Therapeutics reported for 2022 q3
SEC form 10
2022-08-04 00:00 ET
Anika Therapeutics reported for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Anika Therapeutics reported for 2022 q2
SEC form 10
2022-05-06 00:00 ET
Anika Therapeutics reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Anika Therapeutics reported for 2022 q1
SEC form 10
2022-03-11 00:00 ET
Anika Therapeutics published news for 2021 q4
SEC form 8
2022-03-08 00:00 ET
Anika Therapeutics published news for 2021 q4
SEC form 10
2021-11-05 00:00 ET
Anika Therapeutics published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Anika Therapeutics published news for 2021 q3
SEC form 10
2021-08-06 00:00 ET
Anika Therapeutics published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Anika Therapeutics published news for 2021 q2
SEC form 10
2021-05-07 00:00 ET
Anika Therapeutics published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Anika Therapeutics published news for 2021 q1